Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Annual Meeting of Stockholders is scheduled for September 24, 2026, with voting eligibility as of July 31, 2026.

• Focus remains on advancing oral blarcamesine for Alzheimer's, Rett syndrome, and Fragile X syndrome, with active FDA engagement and regulatory execution.

• Board has been refreshed, with half of the members new since the start of 2026, emphasizing independence and relevant expertise.

• Special Committee appointed interim leadership and new nominees to maintain momentum in clinical and regulatory programs.

• Forward-looking statements caution that actual results may differ due to various risks and uncertainties.

Voting matters and shareholder proposals

• Stockholders are asked to elect six directors: four incumbents and two new independent nominees.

• Voting is encouraged for all six nominees on the WHITE proxy card to ensure continuity and expertise.

• PVG is presenting an alternative slate but is criticized for lacking a clear strategic or regulatory plan.

• Voting can be done online, by phone, or by mail, and votes can be changed before the polls close.

Board of directors and corporate governance

• Six nominees bring expertise in biotechnology, medicine, clinical research, finance, and governance.

• All directors will be independent if the slate is elected, with significant experience in public company oversight.

• Board refreshment aims to provide stability and oversight during a critical phase of execution.